Which companies are Silence Therapeutics PLC Sponsored ADR's closest peers?

The cockpit's peer set: OmniAb (OABI), Fortrea (FTRE), Evotec (EVT.DE), Adlai Nortye Ltd. Sponsored ADR (ANL), Progyny (PGNY), SBC Medical (SBC), Evolent Health (EVH), Oculis (OCS).

Is Silence Therapeutics PLC Sponsored ADR expensive compared with its peers?

On ev / sales it trades at 1,889.5× against a peer median of 1.9×, most expensive of 8 in its peer set.

How has Silence Therapeutics PLC Sponsored ADR stock performed?

Over six months to 6 Nov 2026 the shares returned +183.9% against +9.6% for the median peer; over one year +203.1%.

← CockpitCompetitor Analysis › SLN Silence Therapeutics PLC Sponsored ADROpen in the cockpit ↗

Silence Therapeutics PLC Sponsored ADRSLNCompetitor analysis, valuation and peers

United States · USD·Health Care›Miscellaneous Commercial Services

Momentum leader 100

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$1.23B

US dollars, full cap

Free float

84%

of shares outstanding

$/day

$111M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 11.5%

Hurdle

n/a

no reverse DCF

Next earnings

11 days

17 Nov 2026

Close · USD$19.73

1D+0.1%

1W-0.1%

1M+107.2%

3M+65.1%

6M+183.9%

YTD+224.5%

1Y+203.1%

ATR %2.8%

Beta1.36

52w lowhigh0.7% off high

What Silence Therapeutics PLC Sponsored ADR does

Employees: 88

Silence Therapeutics PLC Sponsored ADR at a glance

Size Silence Therapeutics PLC Sponsored ADR (SLN) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $1.23B, the 2124th largest of 3,117 United States companies the cockpit tracks. Shares closed at $19.73 on 6 Nov 2026.

Performance Over six months the shares gained 183.9%, against +9.6% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 10 in its peer set.

Growth Revenue fell 97.3% over the last twelve months (peer median -3.9%); the operating margin is -10,478.2% (peer median -1.3%).

Valuation It trades at 1,889.5× enterprise value to sales against a peer median of 1.9× (most expensive of 8).

Short interest Short interest is 4.7% of the free float (15 Oct 2026).

Next results Next results expected around 17 Nov 2026 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Silence Therapeutics PLC Sponsored ADR against the median of its 9 peers (local-currency closes).

Silence Therapeutics PLC Sponsored ADR financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	$613,251	$560,306	$43.3M	$31.8M	$21.6M
Revenue growth	—	-99%	+36%	+47%	—
Gross profit	$97,035	-$55,129	$31.2M	$18.6M	$7.56M
EBITDA	-$63.8M	-$81.9M	-$49.0M	-$52.0M	-$59.3M
Net income	-$59.8M	-$88.8M	-$45.3M	-$54.4M	-$49.9M
Free cash flow	-$42.1M	-$62.5M	-$67.9M	-$49.7M	-$56.1M
Capital expenditure	$2,682	$55,129	$211,089	$56,217	$541,983
Total debt	$112,000	$160,000	$117,000	$346,000	$536,493

Quarterly statements and history in the cockpit →

Silence Therapeutics PLC Sponsored ADR competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Silence Therapeutics PLC Sponsored ADR is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Silence Therapeutics PLC Sponsored ADR is the large dot.

Silence Therapeutics PLC Sponsored ADR competitors and peer comparison

How Silence Therapeutics PLC Sponsored ADR compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Silence Therapeutics PLC Sponsored ADR against its 9 peers (data as of 6 Nov 2026)
Measure	SLN	Peer median	Rank in peer set
1-month return	+107.2%	-2.6%	highest of 10
6-month return	+183.9%	+9.6%	highest of 10
Distance from 52-week high	-0.7%	-27.7%	highest of 10
Revenue growth (TTM)	-97.3%	-3.9%	lowest of 7
Operating margin	-10,478.2%	-1.3%	lowest of 8
EV / Sales	1,889.5×	1.9×	most expensive of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Silence Therapeutics PLC Sponsored ADR SLN	United States	$1.23B	+184%	-97%	-10,478%	1,889.5×	n/a	n/a
OmniAb OABI	United States	$734M	+29%	+91%	-116%	17.1×	59.6%	-31.9%
Fortrea FTRE	United States	$2.12B	+42%	-3%	2%	1.1×	32.9%	+1.1%
Evotec EVT.DE	Germany	$630M	-33%	-8%	-19%	0.8×	n/a	n/a
Adlai Nortye Ltd. Sponsored ADR ANL	United States	$619M	-23%	n/a	-134%	22.8×	n/a	n/a
Progyny PGNY	United States	$2.67B	+47%	+6%	9%	1.9×	10.4%	+30.2%
SBC Medical SBC	United States	$518M	+58%	-7%	37%	2.3×	-16.1%	-6.9%
Evolent Health EVH	United States	$518M	+10%	-4%	-1%	0.6×	22.6%	+15.2%
Oculis OCS	United States	$462M	-77%	n/a	n/a	n/a	n/a	n/a
Tectonic Therapeutic TECX	United States	$403M	-29%	n/a	n/a	n/a	n/a	n/a

Questions

Which companies are Silence Therapeutics PLC Sponsored ADR's closest peers?: The cockpit's peer set: OmniAb (OABI), Fortrea (FTRE), Evotec (EVT.DE), Adlai Nortye Ltd. Sponsored ADR (ANL), Progyny (PGNY), SBC Medical (SBC), Evolent Health (EVH), Oculis (OCS).
Is Silence Therapeutics PLC Sponsored ADR expensive compared with its peers?: On ev / sales it trades at 1,889.5× against a peer median of 1.9×, most expensive of 8 in its peer set.
How has Silence Therapeutics PLC Sponsored ADR stock performed?: Over six months to 6 Nov 2026 the shares returned +183.9% against +9.6% for the median peer; over one year +203.1%.